How large is the gonorrhea therapeutics market, and what is its growth trajectory?
The gonorrhea therapeutics market size has grown strongly in recent years. It will grow from $1.88 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to the growing resistance of Neisseria gonorrhoeae, rising prevalence of gonorrhea, increasing prevalence of antimicrobial resistance (AMR), increasing antibiotic resistance, and increasing use of dual therapy treatments.
The gonorrhea therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.42 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing sexually transmitted infections, a growing focus on personalized medicine, rising antibiotic resistance patterns, a growing incidence of gonorrhea, and growing demand for effective treatment. Major trends in the forecast period include technological developments, advanced diagnostic tests, the development of new therapeutics, the development of combination therapies, and regulatory support for expedited drug approvals.
Get Your Free Sample of The Global Gonorrhea Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21195&type=smp
What are the key forces behind the gonorrhea therapeutics market’s growth in recent years?
The increasing sexually transmitted infection is expected to propel the growth of the gonorrhea therapeutics market going forward. A sexually transmitted infection (STI) is an infection transmitted through sexual contact, caused by bacteria, viruses, or parasites. The increase in sexually transmitted infections (STIs) is due to factors such as unprotected sex, lack of awareness or education, increased number of sexual partners, reduced use of condoms, and delayed or inadequate testing and treatment. Gonorrhea therapeutics are used to treat sexually transmitted infections by targeting the neisseria gonorrhoeae bacteria, preventing complications and transmission. For instance, in June 2024, according to a report published by the National Institute for Public Health and the Environment, a Netherlands-based government agency, the number of gonorrhea cases diagnosed at SHCs saw a significant year-over-year increase, rising from 10,600 in 2022 to 13,853 in 2023, reflecting a 31% growth. Therefore, the increasing sexually transmitted infection is driving the growth of the gonorrhea therapeutics market.
What are the major segments of the gonorrhea therapeutics market?
The gonorrhea therapeutics market covered in this report is segmented –
1) By Therapeutic Class: Antibiotics, Combination Therapy, Monotherapy
2) By Route Of Administration: Oral, Intravenous, Intramuscular
3) By Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Clinics, Home Care
Subsegments:
1) By Antibiotics: Beta-lactams, Macrolides, Fluoroquinolones, Aminoglycosides
2) By Combination Therapy: Dual Antibiotic Therapy, Triple Antibiotic Therapy
3) By Monotherapy: Single Antibiotic Treatment, Other Monotherapy Options
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/gonorrhea-therapeutics-global-market-report
Which companies dominate the gonorrhea therapeutics market?
Major companies operating in the gonorrhea therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, GlaxoSmithKline plc, Becton Dickinson and Company, Hologic Inc., Aurobindo Pharma Limited, Innoviva Inc., Debiopharm Group, Achilles Vaccines S.r.l., Melinta Therapeutics LLC, VenatoRx Pharmaceuticals Inc., Evofem Biosciences Inc., Recce Pharmaceuticals Ltd., Therapyx Inc., Entasis Therapeutics Inc., Apotex Inc., Alopexx Pharmaceuticals LLC, Summit Therapeutics Inc.
What major trends will shape the gonorrhea therapeutics market during the forecast period?
Major companies operating in the gonorrhea therapeutics market are developing innovative products, such as rapid polymerase chain reaction (PCR) tests, to provide quick, accurate detection of pathogens and their characteristics, such as antibiotic resistance, at the point of care. A rapid polymerase chain reaction (PCR) test is a diagnostic method that quickly amplifies and detects specific DNA or RNA sequences, enabling fast identification of pathogens or genetic material. For instance, in February 2024, Visby Medical, Inc., a US-based medical technology company, launched a gonorrhea test that includes an antimicrobial resistance check. This rapid diagnostic test is designed to detect the presence of Neisseria gonorrhoeae, the bacterium responsible for gonorrhea, and assess its susceptibility to ciprofloxacin, an antibiotic to which some strains of gonorrhea have developed resistance. The test is part of a portable, instrument-free PCR platform, allowing for immediate testing at the point of care. It was developed with funding from the US non-profit organization CARB-X, and the company plans to expand the test to include detection of other sexually transmitted infections, such as Chlamydia trachomatis and Trichomonas vaginalis, in men.
What are the key regional dynamics of the gonorrhea therapeutics market, and which region leads in market share?
North America was the largest region in the gonorrhea therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gonorrhea therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Gonorrhea Therapeutics Market Report 2025 Offer?
The gonorrhea therapeutics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Gonorrhea therapeutics are treatments and medications designed to manage and cure gonorrhea, a sexually transmitted infection (STI) caused by the bacterium neisseria gonorrhoeae. These therapies mainly rely on antibiotics, as the infection is usually treated with a combination of drugs to prevent resistance and ensure effective eradication of the bacteria.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21195
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
